Cite
HARVARD Citation
Alistar, A. et al. (n.d.). Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet oncology. 18 (6), pp. 770-778. [Online].